DierynckI, De WitM, GustinEet al.Binding kinetics of darunavir to human immunodeficiency virus type 1 protease explain the potent antiviral activity and high genetic barrier. J Virol, 2007; 81:13845–13851.
2.
ClotetB, BellosN, MolinaJMet al.POWER 1 and 2 study groups. Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: A pooled subgroup analysis of data from two randomised trials. Lancet, 2007; 369:1169–1178.
3.
MolinaJM, CohenC, KatlamaCet al.TMC114-C208 Study Group; TMC114-C215 Study Group. Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3. J Acquir Immune Defic Syndr, 2007; 46:24–31.
4.
MadrugaJV, BergerD, McMurchieMet al.TITAN study group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: A randomised controlled phase III trial. Lancet, 2007; 370:49–58.
5.
KatlamaC, EspositoR, GatellJMet al.POWER 1 study group. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS, 2007; 21:395–402.
6.
HaubrickR, BergerD, ChiliadePet al.Week 24 efficacy and safety of TMC114 ritonavir in treatment-experienced HIV patients. AIDS, 2007; 21:F11–F18.
7.
OrtizR, DejesusE, KhanlouHet al.Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48. AIDS, 2008; 22:1389–1397.
8.
LanzafameM, BonoraS, LattuadaE, CalcagnoA, VentoS. A reduced dose of darunavir/ritonavir is effective in PI-experienced patients. Braz J Infect Dis, 2011; 15:498–500.
9.
D'AvolioA, BaiettoL, SiccardiMet al.An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit, 2008; 30:662–669.
10.
McKeageK, PerryCM, KeamSJ. Darunavir: A review of its use in the management of HIV infection in adults. Drugs, 2009; 69:477–503.
11.
SekarV, AbeeleCV, Van BaelenBet al.Pharmacokinetic/pharmacodynamic analyses of once-daily darunavir in the ARTEMIS Study. 15th Conference on Retroviruses and Opportunistic Infections, Boston MA, USA, February3–6, 2008Abs 769.
12.
SekarV, De La RosaG, de CasteleTet al.Pharmacokinetic (PK) and pharmacodynamic (PD) analyses of once- and twice-daily darunavir/ritonavir in the ODIN Trial. J Int AIDS Soc, 2010; 13:98.
